Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...
It has been a turbulent time for the pharmaceutical industry – especially in regard to the clinical trial sector. From reduced investment, to a lack of public trust in the industry, it has been ...
A final discussion point is real-world applicability. Although PHAROS presents exceptional PFS, the modest difference between ...
Daedalus, Vol. 154, No. 2, The Ethics of Social Research: Perspectives from the Study of the Middle East & North Africa (Spring 2025), pp. 157-168 (12 pages) As the Middle East and North Africa (MENA) ...
Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
12don MSNOpinion
Why you should be pleased we run trials on nudges, even if you don't like nudges (or trials)
Last year, we ran a randomized controlled trial working with frontline workers in the homelessness sector, which aimed to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback